QCG
PTLA

Quadrant Capital Group’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Quadrant Capital Group’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-200
Closed -$10K – 2077
2015
Q4 		$10K Buy
+200
New +$9.7K 0.01% 813

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Quadrant Capital Group's PTLA Position: Q1 2016 in Review

Quadrant Capital Group sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2016, closing a stake of 200 shares — an estimated $10K sold.

Quadrant Capital Group first reported a position in PTLA in Q4 2015 and held it in 1 quarter. The position peaked at $10K in Q4 2015. 167 funds tracked by Wall St. Rank hold PTLA as of Q1 2016.

  • Quadrant Capital Group reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • Quadrant Capital Group sold 200 Portola Pharmaceuticals, Inc. shares in Q1 2016, an estimated $10K.
  • Quadrant Capital Group first reported a position in Portola Pharmaceuticals, Inc. in Q4 2015 and held it in 1 quarter.
  • Quadrant Capital Group's Portola Pharmaceuticals, Inc. position peaked at $10K in Q4 2015.
  • 167 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2016.

Based on Quadrant Capital Group's 13F filing for Q1 2016, filed 27 Apr 2016.